Abstract
Colorectal cancer (CRC) is one of the most common cancers globally and is associated with a high mortality rate. The transforming growth factor beta (TGF-β) signaling pathway plays an important role in normal intestinal tissue function, but has also been implicated in the development of CRC. MicroRNAs (miRNAs) have also recently emerged as important regulators of cancer development and progression. They act by targeting multiple signaling pathways including the TGF-β signaling pathway. There is growing evidence demonstrating that miRNAs target various components of the TGF-β signaling pathway, including TGF-β1, TGF-β2, regulatory SMADs (SMAD1, 2, 3, 5 and 9), co-mediator SMAD4, inhibitory SMADs (SMAD6 and 7) and the TGF-β receptors, and thereby alter the proliferation and migration of CRC cells. In this review, we summarize the data concerning the interaction between TGF-β signaling pathway and miRNAs with the aim to better understanding the CRC molecular mechanisms and hence better management of this disease.
Keywords: SLCO1B1, atorvastatin, safety, lipid-lowering effects, meta-analysis, colorectal cancer.
Current Pharmaceutical Design
Title:The Role of TGF-β Signaling Regulatory MicroRNAs in the Pathogenesis of Colorectal Cancer
Volume: 24 Issue: 39
Author(s): Reyhaneh Moradi-Marjaneh, Majid Khazaei, Gordon A. Ferns and Seyed H. Aghaee-Bakhtiari*
Affiliation:
- Bioinformatics Research Group, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: SLCO1B1, atorvastatin, safety, lipid-lowering effects, meta-analysis, colorectal cancer.
Abstract: Colorectal cancer (CRC) is one of the most common cancers globally and is associated with a high mortality rate. The transforming growth factor beta (TGF-β) signaling pathway plays an important role in normal intestinal tissue function, but has also been implicated in the development of CRC. MicroRNAs (miRNAs) have also recently emerged as important regulators of cancer development and progression. They act by targeting multiple signaling pathways including the TGF-β signaling pathway. There is growing evidence demonstrating that miRNAs target various components of the TGF-β signaling pathway, including TGF-β1, TGF-β2, regulatory SMADs (SMAD1, 2, 3, 5 and 9), co-mediator SMAD4, inhibitory SMADs (SMAD6 and 7) and the TGF-β receptors, and thereby alter the proliferation and migration of CRC cells. In this review, we summarize the data concerning the interaction between TGF-β signaling pathway and miRNAs with the aim to better understanding the CRC molecular mechanisms and hence better management of this disease.
Export Options
About this article
Cite this article as:
Moradi-Marjaneh Reyhaneh , Khazaei Majid , Ferns A. Gordon and Aghaee-Bakhtiari H. Seyed*, The Role of TGF-β Signaling Regulatory MicroRNAs in the Pathogenesis of Colorectal Cancer, Current Pharmaceutical Design 2018; 24 (39) . https://dx.doi.org/10.2174/1381612825666190110150705
DOI https://dx.doi.org/10.2174/1381612825666190110150705 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Current Pharmaceutical Biotechnology Regulation of EMT by KLF4 in Gastrointestinal Cancer
Current Cancer Drug Targets Methylation of ZNF331 Promotes Cell Invasion and Migration in Human Esophageal Cancer
Current Protein & Peptide Science Editorial (Thematic Issue: Polymers in Drug Delivery)
Current Pharmaceutical Design Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma
Current Drug Discovery Technologies Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy
Current Cancer Therapy Reviews Pharmacogenomics of 5-Fluorouracil/Oxaliplatin in Colorectal Cancer
Current Pharmacogenomics Respiratory Failure in Cancer Patients: Non-Infectious Complications of Antineoplastic Agents for Solid Tumors
Current Respiratory Medicine Reviews The Association Between the Chronic Use of Non-Steroidal Anti- Inflammatory Drugs and Oxidative and Inflammatory Markers in the Elderly
Inflammation & Allergy - Drug Targets (Discontinued) Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters?
Current Medicinal Chemistry State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Recent Patents on Anti-Cancer Drug Discovery Bioinformatics Approaches for Anti-cancer Drug Discovery
Current Drug Targets Chemotherapeutic Options for Colorectal Cancer Patients with Cardiovascular Diseases.
Reviews on Recent Clinical Trials Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Alternative Splice Variants of Survivin as Potential Targets in Cancer
Current Drug Discovery Technologies Methodological Issues of Clinical Research with EGFR Inhibitors
Current Cancer Therapy Reviews Furanodienone: An Emerging Bioactive Furanosesquiterpenoid
Current Organic Chemistry Novel Pharmacologic Approaches to the Prevention and Treatment of Ulcerative Colitis
Current Pharmaceutical Design